Christopher L. Morton

11.1k total citations
128 papers, 5.6k citations indexed

About

Christopher L. Morton is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Christopher L. Morton has authored 128 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Molecular Biology, 32 papers in Neurology and 30 papers in Oncology. Recurrent topics in Christopher L. Morton's work include Neuroblastoma Research and Treatments (31 papers), Cancer therapeutics and mechanisms (30 papers) and Cholinesterase and Neurodegenerative Diseases (19 papers). Christopher L. Morton is often cited by papers focused on Neuroblastoma Research and Treatments (31 papers), Cancer therapeutics and mechanisms (30 papers) and Cholinesterase and Neurodegenerative Diseases (19 papers). Christopher L. Morton collaborates with scholars based in United States, Australia and United Kingdom. Christopher L. Morton's co-authors include Peter J. Houghton, Philip M. Potter, Mary K. Danks, Malcolm A. Smith, C. Patrick Reynolds, John M. Maris, Stephen T. Keir, E. Anders Kolb, Richard Görlick and Richard B. Lock and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Christopher L. Morton

127 papers receiving 5.5k citations

Peers

Countries citing papers authored by Christopher L. Morton

Since Specialization

Citations

This map shows the geographic impact of Christopher L. Morton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher L. Morton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher L. Morton more than expected).

Fields of papers citing papers by Christopher L. Morton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher L. Morton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher L. Morton. The network helps show where Christopher L. Morton may publish in the future.

Co-authorship network of co-authors of Christopher L. Morton

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher L. Morton. A scholar is included among the top collaborators of Christopher L. Morton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher L. Morton. Christopher L. Morton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose 2024 ·Journal of Virology ·Kristin Wiggins, (unknown), (unknown), (unknown), Yunyu Spence, Mark A. Brimble, Brandi Livingston, Christopher L. Morton, Paul G. Thomas, Andrea J. Sant, Ted M. Ross, Andrew M. Davidoff, Stacey Schultz‐Cherry	3
2	Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis 2023 ·Molecular Cancer Therapeutics ·(unknown), (unknown), (unknown), Andrew M. Fleming, Hyea Jin Gil, Andrew S. Boghossian, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Christopher L. Morton, Gerard P. Zambetti, Andrew M. Davidoff, Jun Yang, Andrew J. Murphy	1
3	TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC 2022 ·Cancers ·(unknown), Hyea Jin Gil, Emília M. Pinto, (unknown), Andrew M. Fleming, Michael R. Clay, Dongli Hu, Christopher L. Morton, Shondra M. Pruett‐Miller, Baranda S. Hansen, Xiang Chen, (unknown), Yanling Liu, Xiaotu Ma, Jun Yang, Andrew M. Davidoff, Gerard P. Zambetti, Andrew J. Murphy	3
4	AAV Preparations Contain Contamination from DNA Sequences in Production Plasmids Directly Outside of the ITRs 2016 ·UCL Discovery (University College London) ·Margaret A. Brimble, (unknown), Christopher L. Morton, Michael M. Meagher, (unknown), (unknown), (unknown)	1
5	Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent 2013 ·Clinical Cancer Research ·Emília M. Pinto, Christopher L. Morton, Carlos Rodríguez‐Galindo, Lisa M. McGregor, Andrew M. Davidoff, (unknown), Larisa V. Debelenko, Catherine A. Billups, Raul C. Ribeiro, Gerard P. Zambetti	27
6	Inhibition of Type I Interferon-Mediated Antiviral Action in Human Glioma Cells by the IKK Inhibitors BMS-345541 and TPCA-1 2012 ·Journal of Interferon & Cytokine Research ·Ziyun Du, Michael A. Whitt, (unknown), (unknown), Christopher L. Morton, Andrew M. Davidoff, Lawrence M. Pfeffer	34
7	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program 2010 ·Molecular Cancer Therapeutics ·Peter J. Houghton, Christopher L. Morton, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, (unknown), Amy Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith	79
8	The Insulin-like Growth Factor-1 Receptor–Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma 2009 ·Cancer Research ·Raushan T. Kurmasheva, Lorina Dudkin, Catherine A. Billups, Larisa V. Debelenko, Christopher L. Morton, Peter J. Houghton	132
9	microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies 2009 ·Clinical Cancer Research ·Jun S. Wei, Peter A. Johansson, Qingrong Chen, Young Song, Steffen Durinck, Xinyu Wen, Adam Cheuk, Malcolm A. Smith, Peter J. Houghton, Christopher L. Morton, Javed Khan	44
10	Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program 2009 ·Pediatric Blood & Cancer ·Richard Görlick, E. Anders Kolb, Peter J. Houghton, Christopher L. Morton, Doris A. Phelps, Paula Schaiquevich, Clinton F. Stewart, Stephen T. Keir, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, John M. Maris, Jianrong Wu, Malcolm A. Smith	26
11	Molecular Characterization of the Pediatric Preclinical Testing Panel 2008 ·Clinical Cancer Research ·Geoffrey Neale, Xiaoping Su, Christopher L. Morton, Doris A. Phelps, Richard Görlick, Richard B. Lock, C. Patrick Reynolds, John M. Maris, Henry S. Friedman, Jeffrey S. Dome, Joseph D. Khoury, Timothy J. Triche, Robert C. Seeger, Richard J. Gilbertson, Javed Khan, Malcolm A. Smith, Peter J. Houghton	95
12	Pediatric preclinical testing program (PPTP) evaluation of the MEK1/2 inhibitor AZD6244 (ARRY-142886) 2008 ·Cancer Research ·Malcolm A. Smith, Christopher L. Morton, John M. Maris, Joshua Courtright, E. Anders Kolb, Richard Görlick, Hernán Carol, Richard B. Lock, Henry S. Friedman, Stephen T. Keir, Min H. Kang, C. Patrick Reynolds, Peter J. Houghton	1
13	Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis 2007 ·Cancer Research ·Craig C. Whiteford, Sven Bilke, Braden T. Greer, Qingrong Chen, Till Braunschweig, (unknown), Jun S. Wei, Malcolm A. Smith, Peter J. Houghton, Christopher L. Morton, C. Patrick Reynolds, Richard B. Lock, Richard Görlick, Chand Khanna, Carol J. Thiele, Mikiko Takikita, Daniel Catchpoole, Stephen M. Hewitt, Javed Khan	91
14	Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody SCH 717454 2007 ·Molecular Cancer Therapeutics ·Peter J. Houghton, John M. Maris, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernán Carol, Richard Görlick, E. Anders Kolb, (unknown), C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith	1
15	Combination of CP-751871, a human monoclonal antibody against the IGF-1 receptor, with rapamycin results in a highly effective therapy for xenografts derived from childhood sarcomas 2007 ·Molecular Cancer Therapeutics ·Raushan T. Kurmasheva, (unknown), Doris A. Phelps, Christopher L. Morton, Peter J. Houghton	6
16	Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib 2007 ·Molecular Cancer Therapeutics ·Peter J. Houghton, John M. Maris, Joshua Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernán Carol, Richard Görlick, E. Anders Kolb, Nino Keshelava, C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith	1
17	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program 2007 ·Pediatric Blood & Cancer ·Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Nino Keshelava, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith	98
18	Structural Insights into Drug Processing by Human Carboxylesterase 1: Tamoxifen, Mevastatin, and Inhibition by Benzil 2005 ·Journal of Molecular Biology ·Christopher D. Fleming, Sompop Bencharit, Carol C. Edwards, Janice L. Hyatt, Lyudmila Tsurkan, Feng Bai, Charles H. Fraga, Christopher L. Morton, Escher L. Howard-Williams, Philip M. Potter, Matthew R. Redinbo	122
19	Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. 2003 ·PubMed ·Kyoung Jin P. Yoon, (unknown), Christopher L. Morton, William G. Bornmann, Richard Lee, Philip M. Potter, Mary K. Danks	14
20	Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. 2002 ·PubMed ·Lars M. Wagner, Sylvie M. Guichard, (unknown), Christopher L. Morton, (unknown), Richard A. Ashmun, Linda C. Harris, Peter J. Houghton, Philip M. Potter, Mary K. Danks	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact